Form 4 for DNTH Dianthus Therapeutics, Inc. /DE/
Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-16 · accession 0001669866-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-17 | 2026-03-16 | DNTH | Garcia Marino | CEO AND Pres, Dir | M - OptEx | $7.66 | +65.3K | 65.3K | New | +$500.0K |
| DM | 2026-03-17 | 2026-03-16 | DNTH | Garcia Marino | CEO AND Pres, Dir | M - OptEx | $0.00 | -65.3K | 269.4K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-16 | M | A | 59,700 | $6.70 | 59,700 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-16 | M | A | 5,592 | $17.88 | 65,292 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-03-16 | M | D | 59,700 | $0.00 | 41 | D | $6.70 · — to 2031-11-03 | 59,700 Common Stock | (F1) The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vested in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-03-16 | M | D | 5,592 | $0.00 | 269,408 | D | $17.88 · — to 2034-01-23 | 5,592 Common Stock | (F2) The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |